Interleukin-6 (IL-6) is a multifunctional cytokine playing roles in the immune system, hematopoiesis and acute phase reactions. IL-6 also regulates the growth of in various types of human malignant tumors. Here we demonstrate that IL-6-induced gene expression was suppressed by a specific Heat-shock protein 90 (Hsp90) inhibitor, geldanamycin (GA) in human hepatoma Hep3B cells. GA also suppressed the IL-6-induced activation of signal transducer and activator of transcription 3 (STAT3) in a human embryonic kidney carcinoma 293T cells. This inhibitory effect of GA on STAT3 activation was reversed by overexpression of Hsp90. Furthermore, Hsp90 directly bound to STAT3 via its N-terminal region, which interacted with GA. We provide evidence that the action of GA on IL-6 functions was due to the inhibition of direct physical interactions between STAT3 and Hsp90, which represents a novel role of Hsp90 in the IL-6 signaling pathways.
INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates immune and inflammatory responses (1, 2) , and also implicated in IL-6-related diseases (2) . The IL-6 receptor is a heterodimeric complex, consisting of an IL-6 specific ligand-binding subunit, α chain, and a signal-transducing subunit, gp130. Structural analysis has revealed that both subunits belong to the cytokine receptor superfamily, and gp130 is shared by the receptors for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and cardiotropin 1(CT-1) (3, 4) . The binding of IL-6 to α chain leads to the formation of receptor complexes, followed by tyrosine phosphorylation and activation of Janus protein tyrosine kinases (Jaks) and various cellular proteins, including gp130 itself. The activated Jaks, in turn, phosphorylate and activate latent signal transducer and activator of transcription (STAT) family of transcription factors (5, 6) .
One member of the STAT family of proteins is STAT3, which is mainly activated by IL-6 family of cytokines, epidermal growth factor, and leptin (3, 4) . Like other members of the STAT family, STAT3 is tyrosine-phosphorylated by Jaks, upon which it dimerizes, and translocates into the nucleus to activate target genes (5, 6) . It has been shown that the activated STAT3 can mediate cellular transformation (7, 8) and constitutively active STAT3 is found in various types of human malignant tumors (9) . Furthermore, STAT3 has been recently shown to act as an oncoprotein (7).
Molecular chaperones are a group of proteins whose major roles appear to be the prevention of target protein aggregation and the promotion of their correct folding and assembly (10) . Chaperones such as Heat-shock protein (Hsp70) and Hsp40 likely interact with a wide variety of proteins, and thus their involvement in the folding processes is 4 believed to be of a general and universal nature. Another major molecular chaperone, Hsp90 has been shown to interact mainly with proteins involved in transcription regulation and signal transduction pathways, such as steroid hormone receptors, protein kinases and transcription factors (11) (12) (13) (14) (15) (16) (17) (18) . Apparently Hsp90 stabilizes these proteins and keeps them in a conformation amenable to activation under appropriate conditions. Previous studies presented the observation that Hsp90 was overexpressed in a wide variety of cancer cells and in virally transformed cells (19) . It was also demonstrated that overexpression of Hsps in breast cancer cells resulted in the resistance to some forms of chemotherapy (20) . To date, Hsp90 inhibitors, such as geldanamycin, by interacting specifically with a single molecular target, cause the destabilization and eventual degradation of Hsp90 binding proteins, and they have shown promising antitumor activity in preclinical model systems (13, 21, 22) . 
MATERIALS AND METHODS

Reagents and antibodies
Human recombinant IL-6 was a kind gift from Ajinomoto (Tokyo, Japan). Human recombinant soluble IL-6 receptor α (sIL-6Rα) was a kind gift from Dr. Hirano (Osaka Univ., Osaka, Japan). Geldanamycin (GA) was purchased from Calbiochem (San Diego, CA).
Expression vectors, Jak1, FLAG-tagged Hsp90 mutants (16) , FLAG-tagged STAT3 and STAT3-LUC (23) were kindly provided by Dr. J. N. Ihle (St. Jude CRH., Memphis, TN) and Dr. T. Hirano (Osaka Univ., Osaka, Japan), respectively. Myc-tagged STAT3 mutants were described previously (24) . Anti-Myc antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-FLAG M2 antibody was purchased from Upstate Biotechnology (Lake Placid, NY).
Cell culture, transfections, luciferase assays, and cell growth assays
The human hepatoma cell line Hep3B was maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) (25) . Before stimulation, the cells were cultured for 12 h in DMEM containing 1% FCS, followed by treatment with IL-6 and/or GA. Human embryonic kidney carcinoma cell line, 293T was maintained in DMEM containing 10% FCS, transfected by the standard calcium precipitation protocol and followed by treatment with IL-6 and soluble IL-6 receptor α (100ng/ml) in the presence or absence of GA. Luciferase assay was performed as described (26) . The cells were harvested and lysed in 100 μl of PicaGene Reporter Lysis Buffer (Toyo Ink, Tokyo, Japan) and assayed for luciferase and β-galactosidase activities according to the manufacturer's instructions. Luciferase activities were normalized to the β-galactosidase activities. Three or more independent experiments were carried out.
Northern blot analysis
Hep3B cells were maintained as described above. After serum starvation, cells ( 1×10 7 ) were treated with IL-6 (100 ng/ml) and/or geldanamycin (1μM) for 3 or 6 h. Total RNAs were prepared using Iso-Gen (Nippon Gene) and used in Northern analysis according to established procedures. A nylon membrane (Hybond N+, Amersham Pharmacia Biotech)
and radiolabelled cDNA probes, as indicated, were used.
Immunoprecipitation and immunoblotting
The immunoprecipitation and Western blotting were performed as described previously (26) . 
Cross-talk between STAT3 and Hsp90 in 293T cells
To further delineate the effect of GA on IL-6 signaling pathway, we carry out the transient transfection assay in a human embryonic kideney carcinoma cell line, 293T. The IL-6-mediated transcriptional responses through STAT3 were measured by using STAT3-LUC, in which the α2-macroglobulin promoter (23) 
STAT3 and Hsp-90 physically interact in 293T cells
One of the mechanisms that is consistent with the data described above is that there are direct physical interactions between Hsp90 and STAT3. We tested this possibility by co-immunoprecipitation experiments. To activate STAT3 instead of IL-6 stimulation, we coexpressed Jak1 together with STAT3 as described previously (25) . Expression vectors 
Conclusions
In the present study, we have shown that a specific Hsp90 inhibitor, GA suppressed Uncontrolled hyperproduction of IL-6 causes plasmacytosis, hyper-gamma-globulinemia, thrombocytosis, mesangial cell proliferation of the kidney as well as inflammatory symptoms which are frequently observed in autoimmune diseases (2) . IL-6 is also involvement in several tumor development and progression (2, 9) . An IL-6 signal transducing molecule, STAT3 is tyrosine-phosphorylated by Jaks, upon which it dimerizes, and translocates into the nucleus to activate IL-6-induced genes (5, 6) . It has been shown that v-Src-or Q205L
Gα 0 -mediated cell transformation required STAT3 activation (7, 8) . Moreover, STAT3 acts as a sole transforming agent (7) . Therefore, interference with IL-6 signal transduction through STAT3 may be useful for autoimmune diseases and anti-cancer therapy.
Hsp90 is an abundant molecule and acts as a molecular chaperone that is involved in the folding of various signaling molecules, such as the tyrosine kinases v-Src and Lck, and serine/threonine kinases Raf1 Akt, Bcr-Abl and Pim-1 (11) (12) (13) (14) (15) (16) (17) . Several transcription factors, such as p53 are also Hsp90 client proteins (18, 21) . The levels of both IL-6 and Hsp90 have been reported to be elevated in patients with active systemic lupus erythematosus (SLE) (28) .
It has been also demonstrated that Hsp90 protein accumulates to increased levels in both hepatoma cells and peripheral blood mononuclear cells treated with IL-6, suggesting that IL-6 is able to activate the Hsp90 gene promoter directly (29) . Indeed, the promoter of Hsp90 gene is shown to be stimulated by both IL-6-activated transcription factors, nuclear factor IL-6 (NF-IL6) and STAT3 (30) . These findings suggest that IL-6 positively regulates Hsp90 expression via STAT3 and Hsp90 stabilizes STAT3 proteins. Further work would be required to assess the possible significance of this cross-talk, and the feedback loop that may be established, in the pathophysiology of disease states.
In this study, we demonstrated that Hsp90 is an important regulator of IL-6 functions via μg of total RNA from Hep3B cells treated with IL-6 (100 ng/ml) and/or GA (1μM) for 3 or 6
h. The fold induction of C/EBPδ expression was shown as the densitometric intensity.
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA is included as a loading control (lower panel). 
